ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1776

Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial

Pamela Weiss1, Cora Sears1, Timothy Brandon1, Rui Xiao2, Tory Aquino3, Kweli Archie1, Aamena Hameed4, English Holland5, Miles Holland5, Asad Khan1, Melanie Kohlheim6, Jennifer Leal7, Lynn Murphy8, Sean Murphy8, Antoinette Neu9, Emily Neu9, Jerome Neu9, Justin Neu9, Rachel Richmond10, Theresa Suplee11, Dylan Suplee11 and Christopher Forrest1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, 3Children's Hospital of Philadelphia, Aliquippa, PA, 4Children's Hospital of Philadelphia, Franklin Park, NJ, 5Children's Hospital of Philadelphia, Williamsburg, VA, 6Children's Hospital of Philadelphia, Granville, OH, 7Children's Hospital of Philadelphia, Columbus, OH, 8Children's Hospital of Philadelphia, Haddon Heights, NJ, 9Children's Hospital of Philadelphia, Sidney, OH, 10Children's Hospital of Philadelphia, Albuquerque, NM, 11Children's Hospital of Philadelphia, Maple Shade, NJ

Meeting: ACR Convergence 2021

Keywords: spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The BACK-OFF JSpA Study is a randomized pragmatic trial that will investigate different TNFi de-escalation strategies for children who have sustained asymptomatic disease. As part of the study design we aimed to identify the most important patient-reported outcomes (PRO) of interest to stakeholders that should be examined as part of the trial.

Methods: To identify the most important outcomes of interest to stakeholders we conducted a discrete choice experiment – a user-friendly, quantitative, choice-based approach to evaluate individuals’ preferences regarding potential PROs (Sawtooth Software). With this software, stakeholders assessed a discrete list of 21 NIH Patient-Reported Outcome Measurement Information System (PROMIS) pediatric domains across four general categories of outcomes: physical health, mental health, social health and global health. PROMIS measures are self-reported instruments designed for use in the general population and chronic medical conditions. Rather than asking stakeholders to “rate” all items at once, only 3 domains were shown at a time. Within each set, stakeholders chose the outcomes they felt were “most” and “least” important to consider during TNFi therapy de-escalation. This process was repeated for 21 sets of unique outcome combinations, with each outcome being shown an equal number of times. Stakeholders were required to make choices instead of expressing the strength of a preference (as would be done with a Likert scale or Delphi rating process). Using this process left no opportunity for scale use bias, where respondents often rate the different attributes similarly.

Results: Fourteen caregivers, 12 patients (ages 9-22 years old), 16 rheumatologists and 3 payors completed the exercise, which took approximately 10 minutes. The discrete choice experiment resulted in an estimate of the relative importance of each outcome and rank (Table). All stakeholder groups agreed that the primary PRO should be “Pain Interference”, a measure that evaluates the effect of pain on a child’s everyday activities, including impact upon social, emotional, mental, and physical health. Patients and caregivers were mostly aligned in their top priorities, with patients valuing physical health domains (50% of top 10) whereas caregivers were more interested in mental health domains (60% of top 10). Rheumatologists and payors were most interested in physical health domains, which were ranked as 80% and 60% of their top 10 PROs, respectively. Overall, the patients had the most diverse set of domains, including at least one of each category in their top 10 rank order of importance. Patients were also the only stakeholders to prioritize an outcome from the “social” category.

Conclusion: The discrete choice experiment resulted in an estimate of the relative importance of each PRO and rank. Patients and caregivers were mostly aligned in their top priorities. The rank-order list directly informed the primary and secondary PROs for our upcoming trial.

Sample question from the discrete choice experiment


Disclosures: P. Weiss, Lilly, 1, 2, Pfizer, 1, 2, Biogen, 2; C. Sears, None; T. Brandon, None; R. Xiao, None; T. Aquino, None; K. Archie, None; A. Hameed, None; E. Holland, None; M. Holland, None; A. Khan, None; M. Kohlheim, None; J. Leal, None; L. Murphy, None; S. Murphy, None; A. Neu, None; E. Neu, None; J. Neu, None; J. Neu, None; R. Richmond, None; T. Suplee, None; D. Suplee, None; C. Forrest, None.

To cite this abstract in AMA style:

Weiss P, Sears C, Brandon T, Xiao R, Aquino T, Archie K, Hameed A, Holland E, Holland M, Khan A, Kohlheim M, Leal J, Murphy L, Murphy S, Neu A, Neu E, Neu J, Neu J, Richmond R, Suplee T, Suplee D, Forrest C. Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/stakeholder-outcome-prioritization-in-the-biologic-abatement-and-capturing-kids-outcomes-and-flare-frequency-in-juvenile-spondyloarthritis-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stakeholder-outcome-prioritization-in-the-biologic-abatement-and-capturing-kids-outcomes-and-flare-frequency-in-juvenile-spondyloarthritis-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology